DLBCL outcomes: much ventured, much GAINED

摘要

There have been many attempts to improve the outcomes of patients with diffuse large B-cell lymphoma (DLBCL). In this issue of Blood, the results of the GAINED study by Le Gouill et al take us on a further twist in this journey.1 GAINED asks first whether employing the glycoengineered type 2 anti-CD20 antibody obinutuzumab rather than rituximab has efficacy benefits and, second, whether a positron emission tomography (PET)-driven approach can be used to identify patients at high risk of failure and to adapt consolidation strategies accordingly.